Your browser doesn't support javascript.
loading
Control of APOBEC3B induction and cccDNA decay by NF-κB and miR-138-5p.
Faure-Dupuy, Suzanne; Riedl, Tobias; Rolland, Maude; Hizir, Zoheir; Reisinger, Florian; Neuhaus, Katharina; Schuehle, Svenja; Remouchamps, Caroline; Gillet, Nicolas; Schönung, Maximilian; Stadler, Mira; Wettengel, Jochen; Barnault, Romain; Parent, Romain; Schuster, Linda Christina; Farhat, Rayan; Prokosch, Sandra; Leuchtenberger, Corinna; Öllinger, Rupert; Engleitner, Thomas; Rippe, Karsten; Rad, Roland; Unger, Kristian; Tscharahganeh, Darjus; Lipka, Daniel B; Protzer, Ulrike; Durantel, David; Lucifora, Julie; Dejardin, Emmanuel; Heikenwälder, Mathias.
Afiliación
  • Faure-Dupuy S; Division of Chronic Inflammation and Cancer, German Cancer Research Center (DKFZ), Heidelberg, Germany.
  • Riedl T; Department of Infectious Diseases, Molecular Virology, Heidelberg University, Heidelberg, Germany.
  • Rolland M; Division of Chronic Inflammation and Cancer, German Cancer Research Center (DKFZ), Heidelberg, Germany.
  • Hizir Z; Faculty of Biosciences, Heidelberg University, Heidelberg, Germany.
  • Reisinger F; Laboratory of Molecular Immunology and Signal Transduction, GIGA-Institute, University of Liège, Liège, Belgium.
  • Neuhaus K; Laboratory of Molecular Immunology and Signal Transduction, GIGA-Institute, University of Liège, Liège, Belgium.
  • Schuehle S; Division of Chronic Inflammation and Cancer, German Cancer Research Center (DKFZ), Heidelberg, Germany.
  • Remouchamps C; Institute of Virology, Helmholtz Zentrum München, Munich, Germany.
  • Gillet N; Division of Chronic Inflammation and Cancer, German Cancer Research Center (DKFZ), Heidelberg, Germany.
  • Schönung M; Division of Chronic Inflammation and Cancer, German Cancer Research Center (DKFZ), Heidelberg, Germany.
  • Stadler M; Faculty of Biosciences, Heidelberg University, Heidelberg, Germany.
  • Wettengel J; Laboratory of Molecular Immunology and Signal Transduction, GIGA-Institute, University of Liège, Liège, Belgium.
  • Barnault R; Integrated Veterinary Research Unit, Namur Research Institute for Life Sciences, Namur, Belgium.
  • Parent R; Faculty of Biosciences, Heidelberg University, Heidelberg, Germany.
  • Schuster LC; Section Translational Cancer Epigenomics, Division of Translational Medical Oncology, German Cancer Research Center (DKFZ) and National Center for Tumor Diseases (NCT), Heidelberg, Germany.
  • Farhat R; Division of Chronic Inflammation and Cancer, German Cancer Research Center (DKFZ), Heidelberg, Germany.
  • Prokosch S; Faculty of Biosciences, Heidelberg University, Heidelberg, Germany.
  • Leuchtenberger C; Institute of Virology, Helmholtz Zentrum München, Munich, Germany.
  • Öllinger R; INSERM, U1052, Cancer Research Center of Lyon (CRCL), University of Lyon (UCBL1), CNRS UMR_5286, Centre Léon Bérard (CLB), Lyon, France.
  • Engleitner T; INSERM, U1052, Cancer Research Center of Lyon (CRCL), University of Lyon (UCBL1), CNRS UMR_5286, Centre Léon Bérard (CLB), Lyon, France.
  • Rippe K; Division of Chromatin Networks, German Cancer Research Center (DKFZ) and Bioquant, Heidelberg, Germany.
  • Rad R; INSERM, U1052, Cancer Research Center of Lyon (CRCL), University of Lyon (UCBL1), CNRS UMR_5286, Centre Léon Bérard (CLB), Lyon, France.
  • Unger K; Division of Chronic Inflammation and Cancer, German Cancer Research Center (DKFZ), Heidelberg, Germany.
  • Tscharahganeh D; Division of Chronic Inflammation and Cancer, German Cancer Research Center (DKFZ), Heidelberg, Germany.
  • Lipka DB; Institute of Molecular Oncology and Functional Genomics, Rechts der Isar University Hospital, Munich, Germany.
  • Protzer U; Institute of Molecular Oncology and Functional Genomics, Rechts der Isar University Hospital, Munich, Germany.
  • Durantel D; Division of Chromatin Networks, German Cancer Research Center (DKFZ) and Bioquant, Heidelberg, Germany.
  • Lucifora J; Institute of Molecular Oncology and Functional Genomics, Rechts der Isar University Hospital, Munich, Germany.
  • Dejardin E; Research Unit of Radiation Cytogenetics, Helmholtz Zentrum München, Neuherberg, Germany.
  • Heikenwälder M; Helmholtz-University Group 'Cell Plasticity and Epigenetic Remodeling', German Cancer Research Center (DKFZ) and Institute of Pathology University Hospital, Heidelberg, Germany.
JHEP Rep ; 3(6): 100354, 2021 Dec.
Article en En | MEDLINE | ID: mdl-34704004
ABSTRACT
BACKGROUND &

AIMS:

Immune-mediated induction of cytidine deaminase APOBEC3B (A3B) expression leads to HBV covalently closed circular DNA (cccDNA) decay. Here, we aimed to decipher the signalling pathway(s) and regulatory mechanism(s) involved in A3B induction and related HBV control.

METHODS:

Differentiated HepaRG cells (dHepaRG) knocked-down for NF-κB signalling components, transfected with siRNA or micro RNAs (miRNA), and primary human hepatocytes ± HBV or HBVΔX or HBV-RFP, were treated with lymphotoxin beta receptor (LTßR)-agonist (BS1). The biological outcomes were analysed by reverse transcriptase-qPCR, immunoblotting, luciferase activity, chromatin immune precipitation, electrophoretic mobility-shift assay, targeted-bisulfite-, miRNA-, RNA-, genome-sequencing, and mass-spectrometry.

RESULTS:

We found that canonical and non-canonical NF-κB signalling pathways are mandatory for A3B induction and anti-HBV effects. The degree of immune-mediated A3B production is independent of A3B promoter demethylation but is controlled post-transcriptionally by the miRNA 138-5p expression (hsa-miR-138-5p), promoting A3B mRNA decay. Hsa-miR-138-5p over-expression reduced A3B levels and its antiviral effects. Of note, established infection inhibited BS1-induced A3B expression through epigenetic modulation of A3B promoter. Twelve days of treatment with a LTßR-specific agonist BS1 is sufficient to reduce the cccDNA pool by 80% without inducing significant damages to a subset of cancer-related host genes. Interestingly, the A3B-mediated effect on HBV is independent of the transcriptional activity of cccDNA as well as on rcDNA synthesis.

CONCLUSIONS:

Altogether, A3B represents the only described enzyme to target both transcriptionally active and inactive cccDNA. Thus, inhibiting hsa-miR-138-5p expression should be considered in the combinatorial design of new therapies against HBV, especially in the context of immune-mediated A3B induction. LAY

SUMMARY:

Immune-mediated induction of cytidine deaminase APOBEC3B is transcriptionally regulated by NF-κB signalling and post-transcriptionally downregulated by hsa-miR-138-5p expression, leading to cccDNA decay. Timely controlled APOBEC3B-mediated cccDNA decay occurs independently of cccDNA transcriptional activity and without damage to a subset of cancer-related genes. Thus, APOBEC3B-mediated cccDNA decay could offer an efficient therapeutic alternative to target hepatitis B virus chronic infection.
Palabras clave

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Idioma: En Revista: JHEP Rep Año: 2021 Tipo del documento: Article País de afiliación: Alemania

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Idioma: En Revista: JHEP Rep Año: 2021 Tipo del documento: Article País de afiliación: Alemania